Hazal Beril Çatalak Yılmaz

Hazal Beril Çatalak Yılmaz

Auto-generated profile, based on publicly available information

Hazal Beril Çatalak Yılmaz

Department of Biological Sciences

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
HYHazal B. Catalak Yilmaz
Hazal B. Catalak Yilmaz
MSMahnoor Sulaiman
Mahnoor Sulaiman
OIOzlem Aybuke Isik
Ozlem Aybuke Isik
OCOnur Cizmecioglu
Onur Cizmecioglu
Objectives: The catalytic subunits of Class IA PI3K, p110α, p110β, and p110δ, phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) on the plasma membrane. In cancer, these catalytic subunits are usually found to be altered or amplified. Because pan-PI3K inhibition results in systemic toxicities, finding specific targets for the ubiquitous PI3K isoforms offers considerable potential for enhancing the effectiveness of PI3K-targeted therapy. Methods: We aim to delineate the isoform-specific druggable targets of the PI3K by deleting PIK3CA (encoding p110α) and PIK3CB (encoding p110β) by Cre mediated excision and ectopically expressing p110α, p110β, or p110δ with or without myristoylation (Myr) tag in mouse embryonic fibroblasts (MEFs). Myr is a lipidation signal that translocates proteins to plasma membrane permanently. This translocation renders p110s constitutively activated as they remain in close proximity to PIP 2 on the membrane. Results: Unique and redundant Akt targets are identified downstream of different PI3K isoforms. mTORC1, one of the targets of fully-activated Akt, has been observed to be differentially regulated in MEFs upon expression of p110α or p110β. The varying dependencies on mTORC1 and Rac1 led us to analyse a potential scaffolding function of p110β with Rac1 to mediate phosphorylation and activation of mTOR using platforms for the modeling of biomolecular complexes. We also documented that p110α and p110β support cell cycle kinetics differentially. Conclusions: This study suggests differential regulation of protein translation, metabolism, cell cycle, and survival signaling downstream of unique p110 targets, underlying the importance of cancer treatment according to the deregulated p110 isoform.

21 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LNLeman Nur Nehri
Leman Nur Nehri
HHH. Hazal Hüsnügil
H. Hazal Hüsnügil
ATAliye Ezgi Güleç Taşkıran
Aliye Ezgi Güleç Taşkıran
HYHazal Beril Çatalak Yılmaz
Hazal Beril Çatalak Yılmaz
AAAybar C Acar
Aybar C Acar
SBSreeparna Banerjee
Sreeparna Banerjee
Cancer cells exposed to nutrient deprivation activate adaptive programs to survive metabolic stress, often acquiring enhanced plasticity and motility. We have previously reported that colon cancer cell lines that survived nutrient depletion underwent partial epithelial–mesenchymal transition (pEMT), which was further exacerbated when these cells also underwent lysosomal alkalinization. Here, we have attempted to dissect the molecular mechanisms that drive the motility and shape change from cobblestone to elongated in subpopulations of cells. Using RNA-seq-based bioinformatic analyses integrated with pathway scoring, protein–protein interaction networks, probabilistic modeling and confirmatory experimental data, we have identified the coordinated activation of sublethal apoptotic signaling, fatty acid oxidation, mitochondrial ROS generation, and Ca²⁺-dependent lysosomal exocytosis in the nutrient-depleted cells. Among these phenotypes, the cells undergoing starvation and lysosomal alkalinization exclusively mediated lysosomal exocytosis and cell motility. Probabilistic modeling further revealed non-linear relationships between metabolic stress signals and cell fate transitions, highlighting heterogeneous lysosomal functions as a key determinant of the altered phenotype of cells under nutrient depletion. Overall, our study has identified that aberrant lysosomal functioning in cells under nutrient depletion can specifically select for a subpopulation of cells that are highly viable, metabolically plastic and capable of motility.

17 June 2026 in ACS Omega
Verified
Journal Article
Open access
MEMelike Ergüven
Melike Ergüven
HYHazal Beril Çatalak Yılmaz
Hazal Beril Çatalak Yılmaz
DLDeniz Lengerli
Deniz Lengerli
RARana Acar
Rana Acar
SBServin Bagheralmoosavi
Servin Bagheralmoosavi
OCOnur Cizmecioglu
Onur Cizmecioglu
Isoxazole derivatives have emerged as promising scaffolds in anticancer drug discovery, yet their therapeutic potential remains to be fully harnessed. Here, we report on the synthesis and biological evaluation of two novel biotin-conjugated isoxazole derivatives (C160 and C161) related to the parent compound EB38. Across a panel of liver, prostate, and breast cancer cell lines, both derivatives exhibited significantly enhanced antiproliferative and pro-apoptotic activities compared to EB38, with consistently lower IC50 values in 2D cultures and superior efficacy in 3D spheroid models. Mechanistic studies revealed that C160 and C161 robustly inhibit phosphorylation of JAK1 and STAT1, thereby suppressing JAK/STAT signaling and inducing apoptotic marker cleavage (PARP, Caspase-3, Caspase-7). Direct target engagement was further validated by CETSA and DARTS assays, which demonstrated thermal and proteolytic stabilization of endogenous JAK1 in the presence of C160. Molecular docking and HADDOCK simulations supported JAK1 as a direct cellular target, with binding affinities comparable to the clinically approved inhibitor Ruxolitinib. Importantly, zebrafish embryotoxicity assays confirmed that these derivatives do not elicit general cytotoxicity, even at doses substantially exceeding those effective in vitro. Collectively, our findings establish biotinylated isoxazole derivatives as potent JAK1-targeting anticancer agents with strong antiproliferative and pro-apoptotic activity, supporting their further development as promising candidates for targeted cancer therapy.